Enhance MD vs Maximus: Semaglutide Pricing and Options
Quick verdict: Enhance MD is the lower-cost entry option with both semaglutide starting at $49 first month and tirzepatide from $99 plus flat-rate pricing, while Maximus offers a simple telemedicine semaglutide program at $132.99/month filled through trusted U.S. pharmacies.
Head-to-head: pricing, compound options, and sourcing
The comparison Enhance MD vs Maximus centers on four clear differences supported by the sources: entry price and introductory offers, availability of tirzepatide, pharmacy sourcing and clinician approval process, and platform scale or track record. Both providers use compounded medications and direct-pay telehealth models, and both note that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
1) Entry pricing and ongoing model
Enhance MD advertises semaglutide from $49 first month and tirzepatide from $99 first month, describing those as the cheapest first-month rates and noting flat-rate pricing thereafter that stays the same at every dose. Maximus is presented at a flat low rate of $132.99/month for semaglutide. The suppliers explicitly state these as direct-pay prices; neither bills insurance in the cited materials.
2) Compound options: semaglutide and tirzepatide
Enhance MD offers both compounded semaglutide and compounded tirzepatide on one platform, which the provider highlights as useful for patients deciding between compounds. Maximus’s materials emphasize semaglutide; the source notes limited published detail on tirzepatide availability for Maximus.
3) Pharmacy sourcing and clinician review
Maximus fills prescriptions through trusted U.S. pharmacies with prescriptions approved by licensed doctors via telemedicine. Enhance MD describes clinician-directed compounds and a clinician review process; its materials also repeat the regulatory note that compounded medications are not FDA-approved.
4) Scale and track record
Enhance MD cites more than 10,000 patients treated as part of its public profile. Maximus is characterized as a smaller or newer platform with a thinner public track record and fewer published reviews in the captured evidence.
Concise comparison table
| Criteria | Enhance MD | Maximus |
|---|---|---|
| Starting semaglutide price | Starting at $49 first month | $132.99/month |
| Starting tirzepatide price | Starting at $99 first month | Limited published detail on tirzepatide availability |
| Pricing model | Flat-rate pricing; same price at every dose | Low flat rate listed at $132.99/month |
| Pharmacy sourcing | Compounded medications offered; not FDA-approved finished products | Compounded in U.S. pharmacies; prescriptions approved by licensed doctors |
| Scale / track record | 10,000+ patients treated (publicly stated) | Smaller, newer platform with fewer public reviews |
| Regulatory note | Compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality | Compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality |
Program features and user experience
Both platforms emphasize telemedicine convenience and a clinician review or approval process. Maximus highlights prescriptions approved by licensed doctors and shipment from trusted U.S. pharmacies with free expedited shipping referenced in the source. Enhance MD emphasizes flat-rate pricing that does not escalate with higher doses and the availability of both compounds on one platform for patients who may want options.
Risks, limits, and regulatory context
Both sources explicitly note that their medications are compounded and not FDA-approved finished products. Enhance MD and Maximus present clinician-directed or doctor-approved telemedicine models; both operate as direct-pay services and do not bill insurance in the provided descriptions.
Conclusion: Choose based on price, compound choice, or pharmacy sourcing
Enhance MD vs Maximus narrows to a few practical decisions: entry cost and compound choice are strongest with Enhance MD according to the sources, while Maximus emphasizes a simple low flat monthly rate, licensed doctor approvals, and U.S. pharmacy fulfillment.
Choose Enhance MD if you prioritize the lowest first-month price for semaglutide starting at $49, want access to tirzepatide from $99 on the same platform, or prefer a flat-rate model that the source describes as the same price at every dose.
Choose Maximus if you prefer prescriptions filled through trusted U.S. pharmacies with licensed doctor approvals and a straightforward $132.99/month semaglutide program as presented in the source.